Eric Lefkofsky’s company is about to make personalized cancer treatment a reality. As the CEO of Tempus, Lefkofsky has spearheaded an initiative that uses big data to personalize different types of cancer treatment. Tempus is a technology company that recently started a deal with Precision HealthAI and CancerLinQ to structure data.
Currently, the CancerLinQ database includes one million records from patients. Precision HealthAI and Tempus will help CancerLinQ analyze their database more efficiently and more quickly than they were previously able to.
In an interview, Tempus CEO Eric Lefkofsky discussed the coming deal. CancerLinQ originally formed by ASCO to address the growing amounts of data that were coming from patient records. Previously, all of this data was locked away in electronic medical records. Now, these records could be used to create new techniques for dealing with different patients. CancerLinQ sought out experienced companies like Tempus to help them analyze the data.
The new analysis will help biotech companies de-identify the data so that it can help companies research and develop new drugs. The data can be used to create better clinical trials and to help oncologists in their practice.
After narrowing the field of applicants, Precision HealthAI and Tempus were chosen because they could commercialize, cleanse and analyze the data. The two companies will complement each other as they work toward the shared goal. At Precision HealthAI, the AI platform will be used to compile, manage and utilize the clinical data. Researchers will be able to effectively analyze the different datasets. Meanwhile, Tempus will create unique datasets by combining molecular and clinical data. This innovative development will allow personalized cancer care to become a reality.
Tempus was founded by Eric Lefkofsky in 2015. While Lefkofsky never planned on working in healthcare, his entire life changed after a close friend was treated for cancer. He noticed how little data and technology were used in the clinical practice. After realizing a need for new technology, Lefkofsky decided to form Tempus. He had spent his entire professional life as a technology entrepreneur. Previously, he co-founded Groupon in 2008 and still serves as the chairman. Over the years, he has founded tech innovators like Echo Global Logistics, Uptake and Innerworkings. Currently, all of these businesses are based in Chicago. With his wife, Lefkofsky has signed on to the Giving Pledge to donate the majority of his fortune to philanthropy.
In 2006, Lefkofsky set up the Lefkofsky Family Foundation with his wife. The private charitable foundation seeks to create high-impact programs to improve individual lives in the community. He also serves as a trustee with the Art Institute of Chicago, Steppenwolf Theatre Company and Lurie Children’s Hospital of Chicago. Other than his work in the technology industry, Lefkofsky also works as an adjunct professor at the University of Chicago. He received his bachelor’s degree from the University of Michigan before graduating from the University of Michigan Law School.
His new venture will change the face of data in treating cancer. With the new partnership, Tempus has a chance to use data to make better, more personalized treatment plans.